{"schema_version":"secwatch.filing_event.v1","accession":"0001636282-24-000039","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.358427+00:00","generated_at":"2026-06-02T06:08:21.152818+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spyre reports Q1 net loss $43.9M; cash $485M; SPY001 on track for FIH Q2 2024","bullets":["Net loss of $43.9M for Q1 2024, including $13.8M non-cash stock comp; vs $18.4M loss in Q1 2023.","Cash, equivalents, marketable securities, and restricted cash total $485M as of March 31, 2024.","Raised $180M in March 2024 private placement; expected runway into 2027 through clinical readouts.","SPY001 (anti-α4β7) cleared 28-day GLP tox; FIH study to start Q2 2024 with interim data expected year-end 2024.","SPY002 (anti-TL1A) on track for FIH in H2 2024; SPY003 (anti-IL-23 p19) candidate nomination set for mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-24-000039","json":"https://secwatch.observer/filing/0001636282-24-000039.json","markdown":"https://secwatch.observer/filing/0001636282-24-000039.md","text":"https://secwatch.observer/filing/0001636282-24-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628224000039/0001636282-24-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628224000039/syre-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:08:21.152818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"886cc8f23a28db3c5c1e9d1b863984b51e59c83d","claim":"Spyre Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"issued a press release announcing its financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628224000039/0001636282-24-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}